These data demonstrate that, as an initial proof-of principle, human LL-37-DC are primed to induce enhanced activation of CD8+ T cells, justifying future evaluation of the translatable potential for the use of LL-37 in the culture of immunotherapeutic DC development toward novel human tumor therapies. This evidence concerns the gene CAMP and neoplasm.